European survey of glycopeptide susceptibility in Staphylococcus spp.

Gian Carlo Schito, Raymond Auckenthaler, Anna Marchese, Adolf Bauernfeind

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To reassess the relative potencies of teicoplanin and vancomycin following several years of clinical usage. Methods: The glycopeptide susceptibilities of clinical isolates of staphylococci collected from 70 hospitals in 1995 were determined using NCCLS (National Committee for Clinical Laboratory Standards) methods. Results: In total, 2885 isolates of Staphylococcus aureus and 1480 isolates of coagulase-negative staphylococci were collected. S. aureus was significantly less susceptible to vancomycin (MIC50 1 mg/L) than teicoplanin (MIC50 0.5 mg/L), but the reverse was the case for S. haemolyticus and S. epidermidis. No S. aureus isolate was resistant (≥ 32 mg/L) to either glycopeptide, but nine isolates of coagulase-negative staphylococci had an MIC of teicoplanin of 32 mg/L. Respiratory isolates of S. aureus were less susceptible to glycopeptides than those from other sites. Staphylococci from Belgium and Italy were less susceptible to teicoplanin than isolates from other countries. Conclusions: This European survey shows that in 10 years of clinical use there have been no major changes in the susceptibility of staphylococci to the glycopeptides.

Original languageEnglish
Pages (from-to)547-553
Number of pages7
JournalClinical Microbiology and Infection
Volume5
Issue number9
Publication statusPublished - Sep 1999

Keywords

  • Europe
  • Glycopeptide
  • Staphylococcus spp.

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'European survey of glycopeptide susceptibility in Staphylococcus spp.'. Together they form a unique fingerprint.

Cite this